CIMA rejects Cephalon bid
Executive Summary
Cephalon's proposal to acquire CIMA at $26 per share does not represent a superior offer to CIMA's proposed merger with aaiPharma, CIMA says Sept. 2. Company received unsolicited takeover bid from Cephalon following announcement of proposed merger with aaiPharma; CIMA was prohibited from entering negotiations with Cephalon unless its board deemed the offer superior to merger plans (1"The Pink Sheet" Aug. 25, 2003, p. 17)...
You may also be interested in...
CIMA negotiations with Cephalon
CIMA reopens negotiations with Cephalon on a proposed merger. CIMA's board previously deemed a bid made by Cephalon of $26 per share insufficient to break CIMA's proposed merger with aaiPharma (1"The Pink Sheet" Sept. 8, 2003, In Brief). Cephalon has presumably increased its offer. CIMA and aaiPharma announced a proposed merger Aug. 5; Cephalon then made an unsolicited takeover bid...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.